{"id":"mitomycin","rwe":[],"_fda":{"id":"9b41ea95-d383-46e8-9823-5d0447dec0ab","set_id":"0171a1c8-c474-4ec1-a11d-6b93a21ca460","openfda":{"nui":["N0000000236","N0000175558"],"unii":["50SG953SK6"],"route":["INTRAVENOUS"],"rxcui":["1740898"],"spl_id":["9b41ea95-d383-46e8-9823-5d0447dec0ab"],"brand_name":["Mitomycin"],"spl_set_id":["0171a1c8-c474-4ec1-a11d-6b93a21ca460"],"package_ndc":["25021-252-51"],"product_ndc":["25021-252"],"generic_name":["MITOMYCIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MITOMYCIN"],"pharm_class_epc":["Alkylating Drug [EPC]"],"pharm_class_moa":["Alkylating Activity [MoA]"],"manufacturer_name":["Sagent Pharmaceuticals"],"application_number":["ANDA216648"],"is_original_packager":[true]},"version":"1","warnings":["WARNINGS Patients being treated with mitomycin must be observed carefully and frequently during and after therapy. The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell count, differential, and hemoglobin. The occurrence of a platelet count below 100,000/mm 3 or a WBC below 4,000/mm 3 or a progressive decline in either is an indication to withhold further therapy until blood counts have recovered above these levels. Patients should be advised of the potential toxicity of this drug, particularly bone marrow suppression. Deaths have been reported due to septicemia as a result of leukopenia due to the drug. Patients receiving mitomycin should be observed for evidence of renal toxicity. Mitomycin should not be given to patients with a serum creatinine greater than 1.7 mg percent. Usage in Pregnancy Safe use of mitomycin in pregnant women has not been established. Teratological changes have been noted in animal studies. The effect of mitomycin on fertility is unknown."],"pregnancy":["Usage in Pregnancy Safe use of mitomycin in pregnant women has not been established. Teratological changes have been noted in animal studies. The effect of mitomycin on fertility is unknown."],"references":["References ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice Pittsburgh, PA: Oncology Nursing Society; 1999:32-41. Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, National Institutes of Health; 1983. US Dept of Health and Human Services, Public Health Service publication NIH 83-2621. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985;253:1590-1591. National Study Commission on Cytotoxic Exposure. – Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115. Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia. 1983;1:426-428. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA-A Cancer J for Clin. 1983;33:258-263. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.). Am J Health SystPharm. 1996;53:1669-1685. SAGENT ® Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60195 (USA) Made in India ©2023 Sagent Pharmaceuticals May 2023 SAGENT Pharmaceuticals ®"],"description":["DESCRIPTION Mitomycin (also known as mitomycin and/or mitomycin-C) is an antibiotic isolated from the broth of Streptomyces caespitosus which has been shown to have antitumor activity. The compound is heat stable, has a high melting point, and is freely soluble in organic solvents. Mitomycin for Injection, USP is a sterile dry mixture of mitomycin and mannitol, which when reconstituted with Sterile Water for Injection provides a solution for intravenous administration. Each Single-Dose vial contains mitomycin 40 mg and mannitol 80 mg. Each mL of reconstituted solution will contain 0.5 mg mitomycin and have a pH between 6.0 and 8.0. Mitomycin is a blue-violet crystalline powder with the molecular formula of C 15 H 18 N 4 O 5 , and a molecular weight of 334.33. Its chemical name is 7-amino-9α-methoxymitosane and it has the following structural formula; Structural Formula"],"precautions":["PRECAUTIONS Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids in patients who had previously or simultaneously received mitomycin. The onset of this acute respiratory distress occurred within minutes to hours after the vinca alkaloid injection. The total number of doses for each drug has varied considerably. Bronchodilators, steroids and/or oxygen have produced symptomatic relief. A few cases of adult respiratory distress syndrome have been reported in patients receiving mitomycin in combination with other chemotherapy and maintained at FIO 2 concentrations greater than 50% perioperatively. Therefore, caution should be exercised using only enough oxygen to provide adequate arterial saturation since oxygen itself is toxic to the lungs. Careful attention should be paid to fluid balance and overhydration should be avoided. Bladder fibrosis/contraction has been reported with intravesical administration (not an approved route of administration), which in rare cases has required cystectomy. Nursing Mothers It is not known if mitomycin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from mitomycin, it is recommended that nursing be discontinued when receiving mitomycin therapy. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Insufficient data from clinical studies of mitomycin are available for patients 65 years of age and older to determine whether they respond differently than younger patients. Post-marketing surveillance suggests that elderly patients may be more susceptible than younger patients to injection site reactions (see ADVERSE REACTIONS: Integument and Mucous Membrane Toxicity ) and hypersensitivity reactions. In general, caution should be exercised when prescribing to elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Mitomycin for Injection, USP is supplied in amber vials as follows: NDC Mitomycin for Injection, USP Package Factor 25021-252-51 40 mg Single-Dose Vial 1 vial per carton Storage Store dry powder at 25°C (77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from light. Avoid excessive heat, over 40°C (104°F). Protect reconstituted solution from light. Store solution under refrigeration 2° to 8°C (36° to 46°F), discard after 14 days. If unrefrigerated, discard after 7 days. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"boxed_warning":["WARNING Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin (see WARNINGS and ADVERSE REACTIONS sections). Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses ≥60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined."],"geriatric_use":["Geriatric Use Insufficient data from clinical studies of mitomycin are available for patients 65 years of age and older to determine whether they respond differently than younger patients. Post-marketing surveillance suggests that elderly patients may be more susceptible than younger patients to injection site reactions (see ADVERSE REACTIONS: Integument and Mucous Membrane Toxicity ) and hypersensitivity reactions. In general, caution should be exercised when prescribing to elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20230524","nursing_mothers":["Nursing Mothers It is not known if mitomycin is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from mitomycin, it is recommended that nursing be discontinued when receiving mitomycin therapy."],"adverse_reactions":["ADVERSE REACTIONS Bone Marrow Toxicity This was the most common and most serious toxicity, occurring in 605 of 937 patients (64.4%). Thrombocytopenia and/or leukopenia may occur anytime within 8 weeks after onset of therapy with an average time of 4 weeks. Recovery after cessation of therapy was within 10 weeks. About 25% of the leukopenic or thrombocytopenic episodes did not recover. Mitomycin produces cumulative myelosuppression. Integument and Mucous Membrane Toxicity This has occurred in approximately 4% of patients treated with mitomycin. Cellulitis at the injection site has been reported and is occasionally severe. Stomatitis and alopecia also occur frequently. Rashes are rarely reported. The most important dermatological problem with this drug, however, is the necrosis and consequent sloughing of tissue which results if the drug is extravasated during injection. Extravasation may occur with or without an accompanying stinging or burning sensation and even if there is adequate blood return when the injection needle is aspirated. There have been reports of delayed erythema and/or ulceration occurring either at or distant from the injection site, weeks to months after mitomycin, even when no obvious evidence of extravasation was observed during administration. Skin grafting has been required in some of the cases. Elderly patients may be more susceptible than younger patients to injection site reactions (see PRECAUTIONS: Geriatric Use ). Renal Toxicity 2% of 1,281 patients demonstrated a statistically significant rise in creatinine. There appeared to be no correlation between total dose administered or duration of therapy and the degree of renal impairment. Pulmonary Toxicity This has occurred infrequently but can be severe and may be life-threatening. Dyspnea with a non-productive cough and radiographic evidence of pulmonary infiltrates may be indicative of mitomycin-induced pulmonary toxicity. If other etiologies are eliminated, mitomycin therapy should be discontinued. Steroids have been employed as treatment of this toxicity, but the therapeutic value has not been determined. A few cases of adult respiratory distress syndrome have been reported in patients receiving mitomycin in combination with other chemotherapy and maintained at FIO 2 concentrations greater than 50% perioperatively. Hemolytic Uremic Syndrome (HUS) This serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia (hematocrit ≤25%), thrombocytopenia (≤100,000/mm 3 ), and irreversible renal failure (serum creatinine ≥1.6 mg/dL) has been reported in patients receiving systemic mitomycin. Microangiopathic hemolysis with fragmented red blood cells on peripheral blood smears has occurred in 98% of patients with the syndrome. Other less frequent complications of the syndrome may include pulmonary edema (65%), neurologic abnormalities (16%), and hypertension. Exacerbation of the symptoms associated with HUS has been reported in some patients receiving blood product transfusions. A high mortality rate (52%) has been associated with this syndrome. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs. Less frequently, HUS has also been reported in patients receiving combinations of cytotoxic drugs not including mitomycin. Of 83 patients studied, 72 developed the syndrome at total doses exceeding 60 mg of mitomycin. Consequently, patients receiving ≥60 mg of mitomycin should be monitored closely for unexplained anemia with fragmented cells on peripheral blood smear, thrombocytopenia, and decreased renal function. The incidence of the syndrome has not been defined. Therapy for the syndrome is investigational. Cardiac Toxicity Congestive heart failure, often treated effectively with diuretics and cardiac glycosides, has rarely been reported. Almost all patients who experienced this side effect had received prior doxorubicin therapy. Acute Side Effects Due to Mitomycin were fever, anorexia, nausea, and vomiting. They occurred in about 14% of 1,281 patients. Other Headache, blurring of vision, confusion, drowsiness, syncope, fatigue, edema, thrombophlebitis, hematemesis, diarrhea, and pain. These did not appear to be dose related and were not unequivocally drug related. They may have been due to the primary or metastatic disease processes. Malaise and asthenia have been reported as part of post-marketing surveillance. Bladder fibrosis/contraction has been reported with intravesical administration (see PRECAUTIONS ). To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["CONTRAINDICATIONS Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes."],"how_supplied_table":["
NDCMitomycin for Injection, USPPackage Factor
25021-252-51 40 mg Single-Dose Vial 1 vial per carton
"],"storage_and_handling":["Storage Store dry powder at 25°C (77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from light. Avoid excessive heat, over 40°C (104°F). Protect reconstituted solution from light. Store solution under refrigeration 2° to 8°C (36° to 46°F), discard after 14 days. If unrefrigerated, discard after 7 days. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. In humans, mitomycin is rapidly cleared from the serum after intravenous administration. Time required to reduce the serum concentration by 50% after a 30 mg bolus injection is 17 minutes. After injection of 30 mg, 20 mg, or 10 mg I.V., the maximal serum concentrations were 2.4 mcg/mL, 1.7 mcg/mL, and 0.52 mcg/mL, respectively. Clearance is effected primarily by metabolism in the liver, but metabolism occurs in other tissues as well. The rate of clearance is inversely proportional to the maximal serum concentration because, it is thought, of saturation of the degradative pathways. Approximately 10% of a dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a dose excreted in urine increases with increasing dose. In children, excretion of intravenously administered mitomycin is similar. Animal Toxicology Mitomycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical dose in man, it produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice."],"indications_and_usage":["INDICATIONS AND USAGE Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy."],"spl_unclassified_section":["SAGENT ® Rx only","STABILITY Unreconstituted mitomycin stored at room temperature is stable for the lot life indicated on the package. Avoid excessive heat (over 40°C, 104°F). Reconstituted with Sterile Water for Injection to a concentration of 0.5 mg per mL, mitomycin is stable for 14 days refrigerated or 7 days at room temperature. Diluted in various I.V. fluids at room temperature, to a concentration of 20 to 40 micrograms per mL: I.V. Fluid Stability 0.9 % Sodium Chloride Injection 12 hours Sodium Lactate Injection 24 hours The combination of mitomycin (5 mg to 15 mg) and heparin (1,000 units to 10,000 units) in 30 mL of 0.9% Sodium Chloride Injection is stable for 48 hours at room temperature. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Mitomycin should be given intravenously only, using care to avoid extravasation of the compound. If extravasation occurs, cellulitis, ulceration, and slough may result. Each Single-Dose vial contains mitomycin 40 mg and mannitol 80 mg. To administer, add Sterile Water for Injection, 80 mL. Shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until solution is obtained. After full hematological recovery (see guide to dosage adjustment) from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m 2 intravenously as a single dose via a functioning intravenous catheter. Because of cumulative myelosuppression, patients should be fully re-evaluated after each course of mitomycin, and the dose reduced if the patient has experienced any toxicities. Doses greater than 20 mg/m 2 have not been shown to be more effective, and are more toxic than lower doses. The following schedule is suggested as a guide to dosage adjustment: Nadir After Prior Dose Leukocytes /mm 3 Platelets / mm 3 Percentage of Prior Dose to be given >4000 >100,000 100% 3000 - 3999 75,000 - 99,999 100% 2000 - 2999 25,000 - 74,999 70% <2000 <25,000 50% No repeat dosage should be given until leukocyte count has returned to 4000/mm 3 and a platelet count to 100,000/mm 3 . When mitomycin is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly. If the disease continues to progress after two courses of mitomycin, the drug should be stopped since chances of response are minimal."],"spl_product_data_elements":["Mitomycin Mitomycin Mitomycin Mitomycin Mannitol"],"spl_unclassified_section_table":["
I.V. FluidStability
0.9 % Sodium Chloride Injection 12 hours
Sodium Lactate Injection 24 hours
"],"dosage_and_administration_table":["
Nadir After Prior Dose
Leukocytes /mm3Platelets / mm3Percentage of Prior Dose to be given
>4000 >100,000 100%
3000 - 3999 75,000 - 99,999 100%
2000 - 2999 25,000 - 74,999 70%
<2000 <25,000 50%
"],"animal_pharmacology_and_or_toxicology":["Animal Toxicology Mitomycin has been found to be carcinogenic in rats and mice. At doses approximating the recommended clinical dose in man, it produces a greater than 100 percent increase in tumor incidence in male Sprague-Dawley rats, and a greater than 50 percent increase in tumor incidence in female Swiss mice."],"package_label_principal_display_panel":["PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label NDC 25021-252-51 Mitomycin for Injection, USP 40 mg per vial Single-Dose Vial WARNING: MUST BE ADMINISTERED INTRAVENOUSLY TO AVOID TISSUE DAMAGE Caution: Cytotoxic Agent PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label"]},"tags":[{"label":"Alkylating Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Indoleamine 2,3-dioxygenase 1","category":"target"},{"label":"IDO1","category":"gene"},{"label":"L01DC03","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Adenocarcinoma of pancreas","category":"indication"},{"label":"Adjunct to incisional glaucoma surgery","category":"indication"},{"label":"Metastatic Gastric Cancer","category":"indication"},{"label":"Kyowa Kirin Co., Ltd.","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antibiotics, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Cross-Linking Reagents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Indicators and Reagents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"},{"label":"Nucleic Acid Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin (see WARNINGS and ADVERSE REACTIONS sections). Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses ≥60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"372 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"159 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"146 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"116 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"108 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"106 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"105 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"104 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"104 reports"},{"date":"","signal":"PANCYTOPENIA","source":"FDA FAERS","actionTaken":"100 reports"}],"commonSideEffects":[{"effect":"Bone Marrow Toxicity","drugRate":"64.4%","_validated":true,"placeboRate":""},{"effect":"Integument and Mucous Membrane Toxicity","drugRate":"4%","_validated":true,"placeboRate":""},{"effect":"Renal Toxicity","drugRate":"2%","_validated":true,"placeboRate":""}],"contraindications":["Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past.","Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes."],"specialPopulations":{"Pregnancy":"Safe use of mitomycin in pregnant women has not been established. Teratological changes have been noted in animal studies. The effect of mitomycin on fertility is unknown.","Geriatric use":"Insufficient data from clinical studies of mitomycin are available for patients 65 years of ages and older to determine whether they respond differently than younger patients. Postmarketing surveillance suggests that elderly patients may be more susceptible than younger patients to injection site reactions (see ADVERSE REACTIONS: Integument and Mucous Membrane Toxicity) and hypersensitivity reactions. In general, caution should be exercised when prescribing to elderly patients, re","Paediatric use":"Safety and effectiveness in pedriatric patients have not been established."}},"trials":[],"aliases":[],"company":"Kyowa Kirin Co., Ltd.","patents":[{"type":"Method of Use","number":"9649428","applicant":"GLAUKOS CORP","territory":"US","tradeName":"MITOSOL","expiryDate":"2029-05-21"},{"type":"Compound","number":"9539241","applicant":"GLAUKOS CORP","territory":"US","tradeName":"MITOSOL","expiryDate":"2028-01-02"},{"type":"Method of Use","number":"10039832","applicant":"UROGEN PHARMA LTD","territory":"US","tradeName":"ZUSDURI","expiryDate":"2031-01-20"},{"type":"Formulation","number":"9950069","applicant":"UROGEN PHARMA LTD","territory":"US","tradeName":"ZUSDURI","expiryDate":"2031-01-20"},{"type":"Formulation","number":"9040074","applicant":"UROGEN PHARMA LTD","territory":"US","tradeName":"ZUSDURI","expiryDate":"2031-01-20"},{"type":"Method of Use","number":"12268745","applicant":"UROGEN PHARMA LTD","territory":"US","tradeName":"JELMYTO","expiryDate":"2031-01-20"},{"type":"Method of Use","number":"12440568","applicant":"UROGEN PHARMA LTD","territory":"US","tradeName":"ZUSDURI","expiryDate":"2031-01-20"},{"type":"Formulation","number":"8186511","applicant":"GLAUKOS CORP","territory":"US","tradeName":"MITOSOL","expiryDate":"2026-07-19"},{"type":"Formulation","number":"7806265","applicant":"GLAUKOS CORP","territory":"US","tradeName":"MITOSOL","expiryDate":"2029-02-01"},{"type":"Formulation","number":"9205075","applicant":"GLAUKOS CORP","territory":"US","tradeName":"MITOSOL","expiryDate":"2026-07-19"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MITOMYCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:06:24.579388+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:06:24.579318+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:07:00.612651+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:06:29.794989+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:06:23.609674+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITOMYCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:06:30.154972+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:22.549771+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:22.549805+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:53.635967+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:22.549821+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:06:31.657636+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL328333/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:06:30.872150+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Bone Marrow Toxicity This was the most common and most serious toxicity, occurring in 605 of 937 patients (64.4%). Thrombocytopenia and/or leukopenia may occur anytime within 8 weeks after onset of therapy with an average time of 4 weeks. Recovery after cessation of therapy was within 10 weeks. About 25% of the leukopenic or thrombocytopenic episodes did not recover. Mitomycin produces cumulative myelosuppression. Integument and Mucous Membrane Toxicity This has occurred in app","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:39.142922+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:43.792807+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216648","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:06:22.549825+00:00"}},"allNames":"mitozytrex","offLabel":[],"synonyms":["mitomycin","mutamycin","Mitomycin C"],"timeline":[{"date":"1981-08-24","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2002-11-14","type":"positive","source":"FDA Orange Book","milestone":"Mitozytrex approved — 5MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2012-02-07","type":"positive","source":"FDA Orange Book","milestone":"Mitosol approved — 0.2MG/VIAL"},{"date":"2020-04-15","type":"positive","source":"FDA Orange Book","milestone":"Jelmyto approved — 40MG/VIAL"},{"date":"2022-12-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Kyowa Kirin Co., Ltd.)"},{"date":"2025-06-12","type":"positive","source":"FDA Orange Book","milestone":"Zusduri approved — 40MG/VIAL"}],"aiSummary":"Mitozytrex, developed by Kyowa Kirin Co., Ltd., is a marketed alkylating agent indicated for disseminated adenocarcinoma of the stomach or pancreas. Its key strength lies in its mechanism of action, which effectively interferes with DNA replication in cancer cells, setting it apart in the treatment landscape. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"1981-08-24","orphan":false,"company":"","regulator":"FDA"},{"date":"2022-12-23","orphan":false,"company":"Kyowa Kirin Co., Ltd.","regulator":"PMDA"}],"brandName":"Mitozytrex","ecosystem":[{"indication":"Adenocarcinoma of pancreas","otherDrugs":[{"name":"erlotinib","slug":"erlotinib","company":"Osi Pharms"},{"name":"fluorouracil","slug":"fluorouracil","company":"Spectrum Pharms"},{"name":"gemcitabine","slug":"gemcitabine","company":"Lilly"},{"name":"irinotecan","slug":"irinotecan","company":"Pfizer Inc"}],"globalPrevalence":null},{"indication":"Adjunct to incisional glaucoma surgery","otherDrugs":[],"globalPrevalence":null},{"indication":"Metastatic Gastric Cancer","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Indoleamine 2,3-dioxygenase 1","novelty":"Follow-on","targets":[{"gene":"IDO1","source":"DrugCentral","target":"Indoleamine 2,3-dioxygenase 1","protein":"Indoleamine 2,3-dioxygenase 1"}],"moaClass":"Alkylating Activity","modality":"Small Molecule","drugClass":"Alkylating Drug [EPC]","explanation":"","oneSentence":"","technicalDetail":"Mitozytrex exerts its effects through the formation of DNA cross-links and interstrand DNA cross-links, ultimately leading to DNA damage and apoptosis in cancer cells."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-08-24, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1819","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MITOMYCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MITOMYCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:49:08.995063","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:07:00.612971+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bleomycin","drugSlug":"bleomycin","fdaApproval":"1973-07-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"plicamycin","drugSlug":"plicamycin","fdaApproval":"1970-05-05","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ixabepilone","drugSlug":"ixabepilone","fdaApproval":"2007-10-16","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"mitomycin","indications":{"approved":[{"id":"mitomycin-disseminated-adenocarcinoma-of","name":"Disseminated adenocarcinoma of the stomach or pancreas","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with disseminated adenocarcinoma of the stomach or pancreas","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with disseminated adenocarcinoma of the stomach or pancreas","diagnosticRequired":null,"brandNameForIndication":"Mitozytrex"},{"id":"mitomycin-palliative-treatment-for-disse","name":"Palliative treatment for disseminated adenocarcinoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with disseminated adenocarcinoma who have failed other treatments","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with disseminated adenocarcinoma who have failed other treatments","diagnosticRequired":null,"brandNameForIndication":"Mitozytrex"}],"offLabel":[{"name":"Corneal Conjunctival Intraepithelial Neoplasm","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":72,"evidenceLevel":"strong"},{"name":"Malignant tumor of anus","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":548,"evidenceLevel":"strong"},{"name":"Malignant tumor of head and/or neck","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":510928,"evidenceLevel":"strong"},{"name":"Malignant tumor of urinary bladder","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":1529,"evidenceLevel":"strong"},{"name":"Non-small cell lung cancer","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":590,"evidenceLevel":"strong"},{"name":"Prevention of Recurrent Bladder Carcinoma","source":"DrugCentral","drugName":"MITOMYCIN","evidenceCount":204,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Bristol","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"bleomycin","brandName":"bleomycin","genericName":"bleomycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"plicamycin","brandName":"plicamycin","genericName":"plicamycin","approvalYear":"1970","relationship":"same-class"},{"drugId":"ixabepilone","brandName":"ixabepilone","genericName":"ixabepilone","approvalYear":"2007","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":["AIDS-Related Anal Carcinoma","Anal Margin Squamous Cell Carcinoma","Anal Non-Keratinizing Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","HIV Infection","Rectal Squamous Cell Carcinoma","Stage II Rectal Cancer AJCC v8","Stage IIB Anal Cancer AJCC v8","Stage III Anal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8"],"enrollment":40,"completionDate":"2031-09-15"},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":["Peritoneal Mesothelioma","Peritoneal Carcinomatosis","Ovarian Cancer","Gastrointestinal Cancer","Appendiceal Cancer","Atypical Mesothelial Proliferation","Colorectal Cancer"],"enrollment":60,"completionDate":"2031-12-30"},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":["Non-Muscle Invasive Bladder Urothelial Carcinoma","Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma","Stage I Bladder Cancer AJCC v8"],"enrollment":160,"completionDate":"2032-02-01"},{"nctId":"NCT07496957","phase":"NA","title":"Preserflo MicroShunt Versus Trabeculectomy","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2026-03-01","conditions":["GLAUCOMA 1, OPEN ANGLE, D (Disorder)"],"enrollment":100,"completionDate":"2028-12-01"},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":["Bladder Urothelial Carcinoma","Muscle Invasive Bladder Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8"],"enrollment":475,"completionDate":"2027-06-01"},{"nctId":"NCT02758951","phase":"PHASE2,PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":["Colorectal Neoplasm","Colorectal Cancer","Colorectal Neoplasms Malignant","Colorectal Carcinoma","Colorectal Adenocarcinoma","Peritoneal Neoplasms","Peritoneal Carcinomatosis","Peritoneal Cancer","Peritoneal Metastases","Peritoneal Neoplasm Malignant Secondary Carcinomatosis","Peritoneal Neoplasm Malignant Secondary"],"enrollment":358,"completionDate":"2029-06-01"},{"nctId":"NCT07487168","phase":"PHASE1","title":"Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":["Peritoneal Carcinomatosis"],"enrollment":24,"completionDate":"2028-03"},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":["Anal Basaloid Carcinoma","Anal Canal Cloacogenic Carcinoma","Anal Canal Squamous Cell Carcinoma","Anal Margin Squamous Cell Carcinoma","Stage I Anal Cancer AJCC v8","Stage IIA Anal Cancer AJCC v8"],"enrollment":252,"completionDate":"2029-12-31"},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":272,"completionDate":"2031-04-14"},{"nctId":"NCT07303257","phase":"","title":"Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-23","conditions":["Glaucoma Eye","Open-angle Glaucoma","Closed-Angle Glaucoma","Pseudo Exfoliative Syndrome","Pigmentary Glaucoma"],"enrollment":132,"completionDate":"2027-08"},{"nctId":"NCT07475286","phase":"PHASE2","title":"Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis","status":"NOT_YET_RECRUITING","sponsor":"Mohammad Haroon Asif Choudry","startDate":"2026-04-30","conditions":["Synchronous Gastric Peritoneal Carcinomatosis","Gastroesophageal Peritoneal Carcinomatosis"],"enrollment":22,"completionDate":"2034-04-30"},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":641,"completionDate":"2032-12-31"},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":220,"completionDate":"2032-03-16"},{"nctId":"NCT05672108","phase":"PHASE2","title":"Phase II Trial of Lung Chemoemobolization","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-12","conditions":["Lung Non-Small Cell Carcinoma","Mediastinal Neoplasm","Pleural Neoplasm","Lung Metastases From Any Primary","Endobronchial Metastases","Colon Cancer","Sarcoma"],"enrollment":30,"completionDate":"2027-10-28"},{"nctId":"NCT03348969","phase":"PHASE4","title":"Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC","status":"COMPLETED","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2017-11-01","conditions":["Bladder Cancer"],"enrollment":120,"completionDate":"2025-12-31"},{"nctId":"NCT07282834","phase":"PHASE2","title":"Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)","status":"RECRUITING","sponsor":"Patrick Wagner, MD, FACS","startDate":"2026-01-05","conditions":["Peritoneal (Metastatic) Cancer","Peritoneal Carcinomatosis","Abdominal Cancer","Abdominal Cancer Patients"],"enrollment":200,"completionDate":"2040-11"},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":["Urinary Bladder Neoplasms"],"enrollment":107,"completionDate":"2025-02-27"},{"nctId":"NCT07425743","phase":"NA","title":"Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-11-07","conditions":["Open Angle Glaucoma (OAG)"],"enrollment":26,"completionDate":"2024-08-01"},{"nctId":"NCT07425054","phase":"PHASE2","title":"HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Dorth","startDate":"2026-03","conditions":["Anal Cancer","HPV-Related Carcinoma","Squamous Cell Carcinoma of the Anus"],"enrollment":33,"completionDate":"2029-01"},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":["NMIBC"],"enrollment":236,"completionDate":"2030-06"},{"nctId":"NCT06513065","phase":"PHASE3","title":"Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-12-04","conditions":["Pseudomyxoma Peritonei"],"enrollment":176,"completionDate":"2029-04"},{"nctId":"NCT01858025","phase":"EARLY_PHASE1","title":"Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":["Carcinoma of the Anal Canal"],"enrollment":25,"completionDate":"2021-11"},{"nctId":"NCT05316181","phase":"PHASE3","title":"CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2022-04-07","conditions":["Epithelial Ovarian Cancer","Platinum Resistant","Recurrent Ovarian","HIPEC","Mitomycin","Cytoreductive Surgery"],"enrollment":140,"completionDate":"2029-12-31"},{"nctId":"NCT01815359","phase":"PHASE2","title":"ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-03","conditions":["Appendix Cancer","Colorectal Cancer"],"enrollment":292,"completionDate":"2026-09"},{"nctId":"NCT05838391","phase":"NA","title":"Adaptive Radiation in Anal Cancer","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-18","conditions":["Anal Squamous Cell Carcinoma"],"enrollment":20,"completionDate":"2028-12-31"},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":["Muscle Invasive Bladder Urothelial Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8"],"enrollment":486,"completionDate":"2030-05-31"},{"nctId":"NCT03386500","phase":"PHASE1,PHASE2","title":"Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2017-11-28","conditions":["Anal Cancer, Squamous Cell Carcinoma","Radiation Exposure"],"enrollment":24,"completionDate":"2029-12"},{"nctId":"NCT07358650","phase":"NA","title":"Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma","status":"RECRUITING","sponsor":"Hexiris Inc","startDate":"2026-01-15","conditions":["Primary Open Angle Glaucoma"],"enrollment":25,"completionDate":"2027-03-15"},{"nctId":"NCT07359547","phase":"NA","title":"Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-01","conditions":["GLAUCOMA 1, OPEN ANGLE, D (Disorder)"],"enrollment":166,"completionDate":"2028-01"},{"nctId":"NCT07350200","phase":"NA","title":"XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications During a Long-Term Follow-Up","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2014-12-02","conditions":["Glaucoma"],"enrollment":150,"completionDate":"2025-11-27"},{"nctId":"NCT06774131","phase":"PHASE3","title":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","status":"RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2025-08-06","conditions":["Upper Urinary Tract Urothelial Carcinoma","Urothelial Carcinoma"],"enrollment":70,"completionDate":"2027-10"},{"nctId":"NCT07349043","phase":"PHASE1","title":"A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01","conditions":["Peritoneal Metastasis","CRC (Colorectal Cancer)"],"enrollment":42,"completionDate":"2028-10"},{"nctId":"NCT06331299","phase":"PHASE3","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2024-08-29","conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"enrollment":99,"completionDate":"2026-09"},{"nctId":"NCT07313579","phase":"","title":"Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-12-01","conditions":["Gastric Cancer (GC)","HIPEC","Peritoneal Metastases From Gastric Cancer","Hyperthermic Intraperitoneal Chemoperfusion"],"enrollment":200,"completionDate":"2035-12-01"},{"nctId":"NCT06478862","phase":"PHASE2","title":"Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy","status":"TERMINATED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2024-06-13","conditions":["Cancer of Ovary","Pancreatic Ductal Adenocarcinoma"],"enrollment":19,"completionDate":"2026-01-02"},{"nctId":"NCT04779554","phase":"PHASE2","title":"Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC","status":"RECRUITING","sponsor":"Prakash Pandalai","startDate":"2021-06-04","conditions":["Peritoneal Carcinomatosis"],"enrollment":100,"completionDate":"2026-02"},{"nctId":"NCT01226550","phase":"PHASE1,PHASE2","title":"Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2007-06","conditions":["Peritoneal Carcinosis (PC)"],"enrollment":18,"completionDate":"2011-04"},{"nctId":"NCT05902533","phase":"PHASE2,PHASE3","title":"REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2023-08-14","conditions":["Anal Cancer"],"enrollment":33,"completionDate":"2029-08-14"},{"nctId":"NCT04858009","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-02-15","conditions":["Metastatic Pancreatic Carcinoma","Stage IV Pancreatic Cancer AJCC v8","Metastatic Malignant Neoplasm in the Peritoneum"],"enrollment":40,"completionDate":"2029-07"},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":["Bladder Cancer"],"enrollment":120,"completionDate":"2033-09-30"},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":["Clinical Stage IV Gastric Cancer AJCC v8","Clinical Stage IVA Gastric Cancer AJCC v8","Clinical Stage IVB Gastric Cancer AJCC v8","Malignant Uterine Neoplasm","Metastatic Appendix Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Malignant Neoplasm in the Peritoneum","Metastatic Malignant Solid Neoplasm","Metastatic Ovarian Carcinoma","Pathologic Stage IV Gastric Cancer AJCC v8","Peritoneal Carcinomatosis","Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8","Stage IV Appendix Carcinoma AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Uterine Corpus Cancer AJCC v8","Stage IVA Appendix Carcinoma AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Uterine Corpus Cancer AJCC v8","Stage IVB Appendix Carcinoma AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Uterine Corpus Cancer AJCC v8","Stage IVC Appendix Carcinoma AJCC v8","Stage IVC Colorectal Cancer AJCC v8"],"enrollment":49,"completionDate":"2028-01-05"},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":["Metastatic Appendix Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Malignant Neoplasm in the Peritoneum","Stage IV Appendix Carcinoma AJCC v8","Stage IVC Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma"],"enrollment":129,"completionDate":"2031-02-28"},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":["High-Risk Non-Muscle Invasive Bladder Cancer"],"enrollment":328,"completionDate":"2031-12-01"},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":["Locally Advanced Colorectal Cancer"],"enrollment":1083,"completionDate":"2030-12-31"},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":["Non Muscle Invasive Bladder Cancer","Bladder Cancer","Carcinoma in Situ of Bladder","Urinary Bladder Neoplasms","Carcinoma, Transitional Cell, Bladder"],"enrollment":50,"completionDate":"2027-12-31"},{"nctId":"NCT02369458","phase":"PHASE2","title":"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-04-14","conditions":["Squamous Cell Carcinoma of the Head and Neck","Squamous Cell Carcinoma, Head and Neck"],"enrollment":48,"completionDate":"2024-11-01"},{"nctId":"NCT06822010","phase":"PHASE2","title":"SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-06-01","conditions":["Urinary Bladder Cancer","Upper Tract Urothelial Cancer","Urothelial Cancer"],"enrollment":28,"completionDate":"2029-04-01"},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":["Bladder Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8"],"enrollment":95,"completionDate":"2026-06-30"},{"nctId":"NCT00183885","phase":"PHASE2","title":"A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-10-18","conditions":["Hepatocellular Carcinoma","Liver Cancer"],"enrollment":76,"completionDate":"2023-03-06"},{"nctId":"NCT04107077","phase":"PHASE2","title":"Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-09-09","conditions":["Gastric Cancer","Peritoneal Carcinomatosis"],"enrollment":21,"completionDate":"2026-06-01"},{"nctId":"NCT06781879","phase":"PHASE4","title":"Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Jakob Kristian Jakobsen","startDate":"2025-06-01","conditions":["Non-Muscle Invasive Bladder Cancer"],"enrollment":272,"completionDate":"2032-02-01"},{"nctId":"NCT05040815","phase":"PHASE2","title":"Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-05-11","conditions":["Anal Canal Cancer"],"enrollment":45,"completionDate":"2028-05"},{"nctId":"NCT07152132","phase":"NA","title":"SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-07-20","conditions":["Glaucoma, Open Angle"],"enrollment":50,"completionDate":"2026-12-30"},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":["Urinary Bladder Neoplasms","Carcinoma, Transitional Cell","Carcinoma in Situ of Bladder","Non-Muscle-Invasive Bladder Cancer"],"enrollment":106,"completionDate":"2028-10"},{"nctId":"NCT02701088","phase":"PHASE2","title":"Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2015-12","conditions":["Locally Advanced Anal Canal Cancer"],"enrollment":71,"completionDate":"2025-12"},{"nctId":"NCT06704191","phase":"PHASE1,PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":["Non-Muscle Invasive Bladder Carcinoma","Stage 0a Bladder Cancer AJCC v8","Stage I Bladder Cancer AJCC v8","Stage 0is Bladder Cancer AJCC v8"],"enrollment":40,"completionDate":"2026-06-06"},{"nctId":"NCT06388720","phase":"PHASE2","title":"The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-11-19","conditions":["Bladder Cancer"],"enrollment":82,"completionDate":"2027-12-31"},{"nctId":"NCT07173023","phase":"NA","title":"A Comparative Study of Endoscopic Choanal Canalization and Mitomycin C Application vs Endoscopic Crossover Flap Technique","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":["Choanal Atresia"],"enrollment":30,"completionDate":"2028-09"},{"nctId":"NCT06783569","phase":"PHASE1","title":"A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"JiaRay Group","startDate":"2024-12-31","conditions":["Solid Tumors","Gastric Cancer","Esophagogastric Juction Cancer","Colorectal Cancer"],"enrollment":94,"completionDate":"2026-07"},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":["Anal Cancer"],"enrollment":310,"completionDate":"2030-02-01"},{"nctId":"NCT03648814","phase":"NA","title":"Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT","status":"RECRUITING","sponsor":"Prince of Songkla University","startDate":"2018-08-01","conditions":["Glaucoma, Neovascular","Vascular Endothelial Growth Factor Overexpression"],"enrollment":40,"completionDate":"2026-07-01"},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":["Nasopharyngeal Carcinoma"],"enrollment":10,"completionDate":"2021-12-31"},{"nctId":"NCT04046133","phase":"PHASE1","title":"Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff University","startDate":"2020-10-19","conditions":["Anal Cancer Stage III A","Anal Cancer Stage III B"],"enrollment":52,"completionDate":"2026-11-30"},{"nctId":"NCT02106572","phase":"PHASE3","title":"Therapeutic Instillation of Mistletoe","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abnoba Gmbh","startDate":"2015-04","conditions":["Superficial Bladder Cancer"],"enrollment":548,"completionDate":"2028-12"},{"nctId":"NCT07034651","phase":"NA","title":"Electron Microscopic Examination of Iris Tissue in Buphthalmos","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-06-01","conditions":["Iris Diseases"],"enrollment":20,"completionDate":"2025-06-01"},{"nctId":"NCT06993311","phase":"","title":"Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma","status":"COMPLETED","sponsor":"Xerencia de Xestión Integrada de Ferrol","startDate":"2018-01-01","conditions":["Pseudoexfoliation Syndrome","Pseudoexfoliation Glaucoma in Both Eyes","Open Angle Glaucoma"],"enrollment":350,"completionDate":"2022-12-31"},{"nctId":"NCT06983704","phase":"EARLY_PHASE1","title":"Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-02-09","conditions":["Pediatric Glaucoma"],"enrollment":50,"completionDate":"2025-02-15"},{"nctId":"NCT04200417","phase":"PHASE1","title":"Chemoembolization for Lung Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":["Lung Metastases","Endobronchial Metastases","Pleural Metastases","Mediastinal Metastases"],"enrollment":10,"completionDate":"2022-04-19"},{"nctId":"NCT06944132","phase":"NA","title":"CsA vs MMC for Preventing Pterygium Recurrence","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-04-01","conditions":["Pterygium","Pterygium of the Conjunctiva and Cornea"],"enrollment":40,"completionDate":"2024-10-15"},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":["Kidney Transplantation"],"enrollment":126,"completionDate":"2028-12"},{"nctId":"NCT06735287","phase":"NA","title":"A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":["Bladder Cancer","NMIBC"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":["Bladder Cancer","Non-muscle Invasive"],"enrollment":34,"completionDate":"2027-10-31"},{"nctId":"NCT05494411","phase":"","title":"Named Patient Program for Mitomycin for Pyelocalyceal Solution","status":"AVAILABLE","sponsor":"UroGen Pharma Ltd.","startDate":"","conditions":["Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Carcinoma","Urothelial Carcinoma Recurrent"],"enrollment":0,"completionDate":""},{"nctId":"NCT05874921","phase":"","title":"uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","status":"RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2023-11-17","conditions":["Urothelial Carcinoma","Urothelial Carcinoma Recurrent","Urothelial Carcinoma Ureter","Urothelial Carcinoma Ureter Recurrent","Urothelial Cancer of Renal Pelvis","Urothelial Carcinoma of the Renal Pelvis and Ureter","Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis"],"enrollment":400,"completionDate":"2028-01"},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":["GIST, Malignant","Liver Metastases"],"enrollment":238,"completionDate":"2023-05-01"},{"nctId":"NCT05430035","phase":"EARLY_PHASE1","title":"Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2022-06-23","conditions":["Gallbladder Adenocarcinoma"],"enrollment":10,"completionDate":"2029-07"},{"nctId":"NCT06696794","phase":"PHASE3","title":"Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients","status":"RECRUITING","sponsor":"Shaogang Wang","startDate":"2025-02-17","conditions":["Non-Muscle-Invasive Bladder Cancer (NMIBC)"],"enrollment":180,"completionDate":"2031-06-30"},{"nctId":"NCT03092518","phase":"PHASE2","title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-05","conditions":["Gastric Adenocarcinoma","Esophagogastric Junction","Gastric Cancer"],"enrollment":27,"completionDate":"2024-07-24"},{"nctId":"NCT03422432","phase":"NA","title":"Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2017-09-28","conditions":["Colorectal Cancer","Peritoneal Metastases"],"enrollment":17,"completionDate":"2024-12-13"},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":["Metastatic Breast Cancer"],"enrollment":1460,"completionDate":"2025-12"},{"nctId":"NCT06768346","phase":"NA","title":"Hyperthermic Intra-Vesical Chemotherapy","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-05-08","conditions":["Bladder Cancer"],"enrollment":259,"completionDate":"2020-05-27"},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":["Colorectal Cancer"],"enrollment":340,"completionDate":"2012-01"},{"nctId":"NCT02710734","phase":"PHASE2","title":"Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2016-02-24","conditions":["Urothelial Carcinoma of the Bladder"],"enrollment":78,"completionDate":"2034-02"},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":["Squamous Cell Carcinoma of the Anus Stage III"],"enrollment":55,"completionDate":"2026-07-05"},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":["Pterygium of Conjunctiva and Cornea","Pterygium of Both Eyes","Pterygium"],"enrollment":70,"completionDate":"2025-09-01"},{"nctId":"NCT01905150","phase":"PHASE2","title":"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer","status":"COMPLETED","sponsor":"Bruckner Oncology","startDate":"2014-08-13","conditions":["Pancreatic Cancer"],"enrollment":34,"completionDate":"2020-01"},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":["Urinary Bladder Neoplasms"],"enrollment":520,"completionDate":"2031-11-01"},{"nctId":"NCT06680245","phase":"PHASE3","title":"Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-12-01","conditions":["Glaucoma"],"enrollment":144,"completionDate":"2026-12-01"},{"nctId":"NCT03658304","phase":"PHASE2","title":"Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-12-05","conditions":["Urothelial Carcinoma"],"enrollment":29,"completionDate":"2023-10-17"},{"nctId":"NCT05243550","phase":"PHASE3","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2022-03-01","conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"enrollment":240,"completionDate":"2028-02"},{"nctId":"NCT02040142","phase":"PHASE2","title":"HIPEC for Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2011-11","conditions":["Peritoneal Carcinomatosis","Colorectal Cancer","Appendiceal Cancer","Peritoneal Mesothelioma","Pseudomyxoma Peritonei","Gastric Cancer"],"enrollment":51,"completionDate":"2024-08-19"},{"nctId":"NCT05250648","phase":"PHASE4","title":"Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)","status":"RECRUITING","sponsor":"Hospital Universitario de Fuenlabrada","startDate":"2022-03-02","conditions":["Peritoneal Carcinomatosis","Colon Cancer"],"enrollment":216,"completionDate":"2029-10"},{"nctId":"NCT06626802","phase":"NA","title":"Steroid Versus Mitomycin-C Use in Pediatric Benign Recurrent Esophageal Stricture","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2023-07-01","conditions":["Esophageal Stricture"],"enrollment":24,"completionDate":"2024-06-30"},{"nctId":"NCT00981656","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-11","conditions":["Bladder Cancer"],"enrollment":37,"completionDate":"2023-08-15"},{"nctId":"NCT03018418","phase":"PHASE2","title":"Proton Therapy in Reducing Toxicity in Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jordan Kharofa","startDate":"2017-01-04","conditions":["Anus Neoplasms"],"enrollment":14,"completionDate":"2025-07-01"},{"nctId":"NCT02891447","phase":"PHASE2","title":"Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-09-01","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Peritoneal Carcinomatosis"],"enrollment":24,"completionDate":"2023-04-11"},{"nctId":"NCT04230759","phase":"PHASE2","title":"Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"Goethe University","startDate":"2020-01-07","conditions":["Anal Cancer","Anal Carcinoma","Anal Cancer Stage III","Anal Cancer Stage II"],"enrollment":180,"completionDate":"2027-03-31"},{"nctId":"NCT05136898","phase":"PHASE3","title":"Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2021-11-30","conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"enrollment":8,"completionDate":"2023-02-02"},{"nctId":"NCT06393855","phase":"NA","title":"Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain","status":"RECRUITING","sponsor":"Dongyang People's Hospital","startDate":"2024-06-18","conditions":["Myopia"],"enrollment":36,"completionDate":"2025-12-31"},{"nctId":"NCT01581840","phase":"PHASE1,PHASE2","title":"Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-01","conditions":["Epidermoid Carcinoma","Anus"],"enrollment":45,"completionDate":"2021-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"MITOMYCIN"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"MUTAMYCIN"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Mitomycin"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146471","MMSL":"1274","NDDF":"002660","UNII":"50SG953SK6","VUID":"4018134","CHEBI":"CHEBI:27504","VANDF":"4018134","INN_ID":"3043","RXNORM":"204298","UMLSCUI":"C0002475","chemblId":"CHEMBL328333","ChEMBL_ID":"CHEMBL105","KEGG_DRUG":"D00208","DRUGBANK_ID":"DB00305","PUBCHEM_CID":"5746","SNOMEDCT_US":"387331000","IUPHAR_LIGAND_ID":"7089","MESH_DESCRIPTOR_UI":"D016685"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Bristol","relationship":"Current Owner"},{"period":"2022","companyName":"Kyowa Kirin Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","fractionUnbound":"0.794%"},"publicationCount":19478,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01DC03","allCodes":["L01DC03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":9,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Bristol Myers","Eugia Pharma","Fresenius Kabi Usa","Gland","Hikma","Hospira","Meitheal","Rk Pharma"],"status":"approved","companyName":"Bristol","companyId":"kyowa-kirin-co-ltd","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-08-24T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-13T00:00:00.000Z","mah":"RK PHARMA","brand_name_local":null,"application_number":"ANDA203386"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-13T00:00:00.000Z","mah":"RK PHARMA","brand_name_local":null,"application_number":"ANDA202670"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-09-08T00:00:00.000Z","mah":"MEITHEAL","brand_name_local":null,"application_number":"ANDA214505"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-11-22T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA216648"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2022-12-23T00:00:00.000Z","mah":"Kyowa Kirin Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-06-12T00:00:00.000Z","mah":"UROGEN PHARMA","brand_name_local":null,"application_number":"NDA215793"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8186511","territory":"US","patent_type":"Formulation","expiry_date":"2026-07-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9205075","territory":"US","patent_type":"Formulation","expiry_date":"2026-07-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9539241","territory":"US","patent_type":"Compound","expiry_date":"2028-01-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7806265","territory":"US","patent_type":"Formulation","expiry_date":"2029-02-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9649428","territory":"US","patent_type":"Method of Use","expiry_date":"2029-05-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12268745","territory":"US","patent_type":"Method of Use","expiry_date":"2031-01-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12440568","territory":"US","patent_type":"Method of Use","expiry_date":"2031-01-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9040074","territory":"US","patent_type":"Formulation","expiry_date":"2031-01-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9950069","territory":"US","patent_type":"Formulation","expiry_date":"2031-01-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10039832","territory":"US","patent_type":"Method of Use","expiry_date":"2031-01-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":12,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T01:07:00.612971+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}